Genmab Relies On Pipeline As J&J Opts Out Of Next-Gen Darzalex
Epkinly, Rina-S, Acasunlimab To Deliver Revenue Growth
J&J’s decision about whether to in-license HexaBody-CD38 (GEN3014) was seen as a key milestone for Genmab this year, but without the opt-in the company is discontinuing development.
